| Combination of | |
|---|---|
| Pioglitazone | Thiazolidinedione |
| Glimepiride | Sulfonylurea |
| Clinical data | |
| Trade names | Duetact, Tandemact |
| AHFS/ Drugs.com | UK Drug Information |
| License data | |
|
Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Pioglitazone/glimepiride, sold under the brand name Duetact among others, is a fixed-dose combination anti-diabetic medication for the treatment of type 2 diabetes. [2] [1] It contains the thiazolidinedione pioglitazone and the sulfonylurea glimepiride. [2] [1] It is taken by mouth. [2] [1]
The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling). [1]
Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. [1] Glimepiride is a sulphonylurea: it stimulates the pancreas to produce more insulin. [1] Pioglitazone/glimepiride was approved for medical use in the United States in July 2006, and in the European Union in January 2007. [1] [3] [4]
Medical uses
In the United States pioglitazone/glimepiride is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone. [2] [3] [5]
In the European Union pioglitazone/glimepiride is indicated for the treatment of people with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride. [1]
References
- ^ a b c d e f g h i "Tandemact EPAR". European Medicines Agency (EMA). Retrieved 27 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d "Duetact- pioglitazone and glimepiride tablet". DailyMed. 5 February 2019. Retrieved 27 July 2020.
- ^
a
b
"Duetact approval letter" (PDF). U.S.
Food and Drug Administration (FDA). 27 July 2006.
This article incorporates text from this source, which is in the
public domain.
- ^ "Drug Approval Package: Duetact (pioglitazone HCl + glimepiride) NDA #021925". U.S. Food and Drug Administration (FDA). 4 September 2008.
- ^ "Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Inf". U.S. Food and Drug Administration (FDA). 8 September 2016. Retrieved 27 July 2020.
External links
- "Glimepiride mixture with pioglitazone hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
- "Glimepiride mixture with pioglitazone". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |